Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Copyright © 2022 Massachusetts Medical Society..
BACKGROUND: The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy. The primary results regarding event-free survival in this trial have not been reported.
METHODS: We randomly assigned, in a 2:1 ratio, patients with previously untreated stage II or III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks plus paclitaxel and carboplatin, followed by four cycles of pembrolizumab or placebo plus doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab-chemotherapy group) or placebo (placebo-chemotherapy group) every 3 weeks for up to nine cycles. The primary end points were pathological complete response (the results for which have been reported previously) and event-free survival, defined as the time from randomization to the date of disease progression that precluded definitive surgery, local or distant recurrence, occurrence of a second primary cancer, or death from any cause. Safety was also assessed.
RESULTS: Of the 1174 patients who underwent randomization, 784 were assigned to the pembrolizumab-chemotherapy group and 390 to the placebo-chemotherapy group. The median follow-up at this fourth planned interim analysis (data cutoff, March 23, 2021) was 39.1 months. The estimated event-free survival at 36 months was 84.5% (95% confidence interval [CI], 81.7 to 86.9) in the pembrolizumab-chemotherapy group, as compared with 76.8% (95% CI, 72.2 to 80.7) in the placebo-chemotherapy group (hazard ratio for event or death, 0.63; 95% CI, 0.48 to 0.82; P<0.001). Adverse events occurred predominantly during the neoadjuvant phase and were consistent with the established safety profiles of pembrolizumab and chemotherapy.
CONCLUSIONS: In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
| Errataetall: |
CommentIn: Nat Rev Clin Oncol. 2022 Apr;19(4):220. - PMID 35217781 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:386 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 386(2022), 6 vom: 10. Feb., Seite 556-567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schmid, Peter [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 17.02.2022 Date Revised 05.05.2022 published: Print ClinicalTrials.gov: NCT03036488 CommentIn: Nat Rev Clin Oncol. 2022 Apr;19(4):220. - PMID 35217781 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2112651 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336715625 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336715625 | ||
| 003 | DE-627 | ||
| 005 | 20231225232754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2112651 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336715625 | ||
| 035 | |a (NLM)35139274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schmid, Peter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.02.2022 | ||
| 500 | |a Date Revised 05.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03036488 | ||
| 500 | |a CommentIn: Nat Rev Clin Oncol. 2022 Apr;19(4):220. - PMID 35217781 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy. The primary results regarding event-free survival in this trial have not been reported | ||
| 520 | |a METHODS: We randomly assigned, in a 2:1 ratio, patients with previously untreated stage II or III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks plus paclitaxel and carboplatin, followed by four cycles of pembrolizumab or placebo plus doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab-chemotherapy group) or placebo (placebo-chemotherapy group) every 3 weeks for up to nine cycles. The primary end points were pathological complete response (the results for which have been reported previously) and event-free survival, defined as the time from randomization to the date of disease progression that precluded definitive surgery, local or distant recurrence, occurrence of a second primary cancer, or death from any cause. Safety was also assessed | ||
| 520 | |a RESULTS: Of the 1174 patients who underwent randomization, 784 were assigned to the pembrolizumab-chemotherapy group and 390 to the placebo-chemotherapy group. The median follow-up at this fourth planned interim analysis (data cutoff, March 23, 2021) was 39.1 months. The estimated event-free survival at 36 months was 84.5% (95% confidence interval [CI], 81.7 to 86.9) in the pembrolizumab-chemotherapy group, as compared with 76.8% (95% CI, 72.2 to 80.7) in the placebo-chemotherapy group (hazard ratio for event or death, 0.63; 95% CI, 0.48 to 0.82; P<0.001). Adverse events occurred predominantly during the neoadjuvant phase and were consistent with the established safety profiles of pembrolizumab and chemotherapy | ||
| 520 | |a CONCLUSIONS: In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a Cortes, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Dent, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Pusztai, Lajos |e verfasserin |4 aut | |
| 700 | 1 | |a McArthur, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Kümmel, Sherko |e verfasserin |4 aut | |
| 700 | 1 | |a Bergh, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a Denkert, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Yeon Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, Rina |e verfasserin |4 aut | |
| 700 | 1 | |a Harbeck, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Masato |e verfasserin |4 aut | |
| 700 | 1 | |a Untch, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Fasching, Peter A |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Patt, Debra |e verfasserin |4 aut | |
| 700 | 1 | |a Danso, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Mouret-Reynier, Marie-Ange |e verfasserin |4 aut | |
| 700 | 1 | |a Im, Seock-Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Jin-Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Gion, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Baron-Hay, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Boileau, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Tryfonidis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Aktan, Gursel |e verfasserin |4 aut | |
| 700 | 1 | |a Karantza, Vassiliki |e verfasserin |4 aut | |
| 700 | 1 | |a O'Shaughnessy, Joyce |e verfasserin |4 aut | |
| 700 | 0 | |a KEYNOTE-522 Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Antill, Yoland |e investigator |4 oth | |
| 700 | 1 | |a Baron-Hay, Sally |e investigator |4 oth | |
| 700 | 1 | |a Hui, Rina |e investigator |4 oth | |
| 700 | 1 | |a Inglis, Po-Ling |e investigator |4 oth | |
| 700 | 1 | |a Murray, Nick |e investigator |4 oth | |
| 700 | 1 | |a Thomson, Jacqui |e investigator |4 oth | |
| 700 | 1 | |a Tsoi, Daphne |e investigator |4 oth | |
| 700 | 1 | |a Barrios, Carlos Henrique E |e investigator |4 oth | |
| 700 | 1 | |a da Cunha, Ademar Dantas |c Jr |e investigator |4 oth | |
| 700 | 1 | |a de Cassia Costamilan, Rita |e investigator |4 oth | |
| 700 | 1 | |a de Figueiredo Chaves, Fabio |e investigator |4 oth | |
| 700 | 1 | |a de Freitas, Ruffo |c Jr |e investigator |4 oth | |
| 700 | 1 | |a Girotto, Gustavo Colagiovanni |e investigator |4 oth | |
| 700 | 1 | |a Linck, Rudinei Diogo Marques |e investigator |4 oth | |
| 700 | 1 | |a Pedrini, Jose Luiz |e investigator |4 oth | |
| 700 | 1 | |a Skare, Nils Gunnar |e investigator |4 oth | |
| 700 | 1 | |a Boileau, Jean-Francois |e investigator |4 oth | |
| 700 | 1 | |a Cescon, David |e investigator |4 oth | |
| 700 | 1 | |a Pavic, Michel |e investigator |4 oth | |
| 700 | 1 | |a Provencher, Louise |e investigator |4 oth | |
| 700 | 1 | |a Poirier, Brigitte |e investigator |4 oth | |
| 700 | 1 | |a Robidoux, Andre |e investigator |4 oth | |
| 700 | 1 | |a Hassan, Saima |e investigator |4 oth | |
| 700 | 1 | |a Song, Xinni |e investigator |4 oth | |
| 700 | 1 | |a Verma, Sunil |e investigator |4 oth | |
| 700 | 1 | |a Webster, Marc |e investigator |4 oth | |
| 700 | 1 | |a Avendano Rojas, Ana Cristina |e investigator |4 oth | |
| 700 | 1 | |a Bruges, Ricardo |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez Fernandez, Manuel Enrique |e investigator |4 oth | |
| 700 | 1 | |a Montoya Restrepo, Maria Elvira |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Diego Mauricio |e investigator |4 oth | |
| 700 | 1 | |a Rojas, Luis Leonardo |e investigator |4 oth | |
| 700 | 1 | |a Sanchez Castillo, Jesus Oswaldo |e investigator |4 oth | |
| 700 | 1 | |a Rojas-Uribe, Gustova Adolfo |e investigator |4 oth | |
| 700 | 1 | |a Bourgeois, Hugues |e investigator |4 oth | |
| 700 | 1 | |a Chieze, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Chocteau-Bouju, Dorothee |e investigator |4 oth | |
| 700 | 1 | |a Dalenc, Florence |e investigator |4 oth | |
| 700 | 1 | |a Delbaldo, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Dohollou, Nadine |e investigator |4 oth | |
| 700 | 1 | |a Giacchetti, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Levy, Christelle |e investigator |4 oth | |
| 700 | 1 | |a Loirat, Delphine |e investigator |4 oth | |
| 700 | 1 | |a Sablin, Marie-Paule |e investigator |4 oth | |
| 700 | 1 | |a Mansi, Laura |e investigator |4 oth | |
| 700 | 1 | |a Mouret-Reynier, Marie-Ange |e investigator |4 oth | |
| 700 | 1 | |a Deryal, Mustafa |e investigator |4 oth | |
| 700 | 1 | |a Fasching, Peter A |e investigator |4 oth | |
| 700 | 1 | |a Harbeck, Nadia |e investigator |4 oth | |
| 700 | 1 | |a Hartkopf, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Kurbacher, Christian Martin |e investigator |4 oth | |
| 700 | 1 | |a Reinisch, Mattea |e investigator |4 oth | |
| 700 | 1 | |a Thomssen, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Untch, Michael |e investigator |4 oth | |
| 700 | 1 | |a Witzel, Isabell |e investigator |4 oth | |
| 700 | 1 | |a Murphy, Conleth |e investigator |4 oth | |
| 700 | 1 | |a Walshe, Janice |e investigator |4 oth | |
| 700 | 1 | |a Geffen, David |e investigator |4 oth | |
| 700 | 1 | |a Tokar, Margarita |e investigator |4 oth | |
| 700 | 1 | |a Katz, Daniella |e investigator |4 oth | |
| 700 | 1 | |a Rasco, Adi |e investigator |4 oth | |
| 700 | 1 | |a Paluch-Shimon, Shani |e investigator |4 oth | |
| 700 | 1 | |a Kaufman, Bella |e investigator |4 oth | |
| 700 | 1 | |a Peretz-Yablonski, Tamar |e investigator |4 oth | |
| 700 | 1 | |a Ryvo, Larisa |e investigator |4 oth | |
| 700 | 1 | |a Evron, Ella |e investigator |4 oth | |
| 700 | 1 | |a Wolf, Ido |e investigator |4 oth | |
| 700 | 1 | |a Stemmer, Salomon |e investigator |4 oth | |
| 700 | 1 | |a Baldini, Editta |e investigator |4 oth | |
| 700 | 1 | |a Beneditti, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Battelli, Nicola |e investigator |4 oth | |
| 700 | 1 | |a Colleoni, Marco |e investigator |4 oth | |
| 700 | 1 | |a De Laurentiis, Michelino |e investigator |4 oth | |
| 700 | 1 | |a Pedersini, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Rocco, Andrea |e investigator |4 oth | |
| 700 | 1 | |a di Giorgi, Ugo |e investigator |4 oth | |
| 700 | 1 | |a Hattori, Masaya |e investigator |4 oth | |
| 700 | 1 | |a Iwata, Hiroji |e investigator |4 oth | |
| 700 | 1 | |a Hayashi, Naoki |e investigator |4 oth | |
| 700 | 1 | |a Inoue, Kenichi |e investigator |4 oth | |
| 700 | 1 | |a Komoike, Yoshifumi |e investigator |4 oth | |
| 700 | 1 | |a Masuda, Norikazu |e investigator |4 oth | |
| 700 | 1 | |a Miyoshi, Yasuo |e investigator |4 oth | |
| 700 | 1 | |a Mukai, Hirofumi |e investigator |4 oth | |
| 700 | 1 | |a Ohno, Shinji |e investigator |4 oth | |
| 700 | 1 | |a Ohtani, Shoichiro |e investigator |4 oth | |
| 700 | 1 | |a Itoh, Mitsuya |e investigator |4 oth | |
| 700 | 1 | |a Saeki, Toshiaki |e investigator |4 oth | |
| 700 | 1 | |a Osaki, Akihiko |e investigator |4 oth | |
| 700 | 1 | |a Sagara, Yasuaki |e investigator |4 oth | |
| 700 | 1 | |a Tamura, Kenji |e investigator |4 oth | |
| 700 | 1 | |a Shimizu, Chikako |e investigator |4 oth | |
| 700 | 1 | |a Yonemori, Kan |e investigator |4 oth | |
| 700 | 1 | |a Takahashi, Masato |e investigator |4 oth | |
| 700 | 1 | |a Takano, Toshimi |e investigator |4 oth | |
| 700 | 1 | |a Tanabe, Yuko |e investigator |4 oth | |
| 700 | 1 | |a Tokuda, Yutaka |e investigator |4 oth | |
| 700 | 1 | |a Niikura, Naoki |e investigator |4 oth | |
| 700 | 1 | |a Tsugawa, Koichiro |e investigator |4 oth | |
| 700 | 1 | |a Watanabe, Junichiro |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 386(2022), 6 vom: 10. Feb., Seite 556-567 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:386 |g year:2022 |g number:6 |g day:10 |g month:02 |g pages:556-567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2112651 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 386 |j 2022 |e 6 |b 10 |c 02 |h 556-567 | ||